CHINARES PHARMA (03320) Income Statement & Earnings

5.250
+0.010+0.19%

Market Closed Apr 30 16:07 CST

32.98BMarket Cap7.36P/E (TTM)

CHINARES PHARMA (03320) Income Statement

All

YOY

Hide blank lines

(FY)Dec 31, 2025

(Q6)Jun 30, 2025

(FY)Dec 31, 2024

(Q6)Jun 30, 2024

(FY)Dec 31, 2023

(Q6)Jun 30, 2023

(FY)Dec 31, 2022

(Q6)Jun 30, 2022

(FY)Dec 31, 2021

(Q6)Jun 30, 2021

Turnover

4.62%269.57B

2.54%131.87B

5.30%257.67B

4.71%128.6B

12.16%244.7B

-2.31%122.82B

-7.86%218.18B

9.81%125.72B

18.15%236.81B

28.08%114.49B

Operating income

4.62%269.57B

2.54%131.87B

5.30%257.67B

4.71%128.6B

12.16%244.7B

-2.31%122.82B

-7.86%218.18B

9.81%125.72B

18.15%236.81B

28.08%114.49B

Cost of sales

-3.72%-225.07B

-2.50%-110.36B

-5.15%-216.98B

-4.47%-107.66B

-11.81%-206.37B

2.67%-103.06B

8.37%-184.56B

-9.13%-105.88B

-19.80%-201.43B

-30.20%-97.02B

Operating expenses

-3.72%-225.07B

-2.50%-110.36B

-5.15%-216.98B

-4.47%-107.66B

-11.81%-206.37B

2.67%-103.06B

8.37%-184.56B

-9.13%-105.88B

-19.80%-201.43B

-30.20%-97.02B

Gross profit

9.39%44.51B

2.75%21.51B

6.13%40.69B

5.94%20.93B

14.04%38.34B

-0.36%19.76B

-4.98%33.62B

13.55%19.83B

9.56%35.38B

17.48%17.47B

Selling expenses

-11.50%-22.09B

-6.74%-10.01B

-4.76%-19.81B

-1.49%-9.38B

-15.34%-18.91B

-1.80%-9.24B

6.48%-16.4B

-9.59%-9.08B

-9.37%-17.53B

-22.35%-8.28B

Administrative expenses

-5.30%-7.08B

-4.67%-3.19B

-6.31%-6.73B

-7.00%-3.04B

-13.44%-6.33B

2.98%-2.85B

10.55%-5.58B

-8.58%-2.93B

-12.07%-6.24B

-25.74%-2.7B

Operating interest expense

----

7.39%-1.36B

12.96%-2.74B

5.32%-1.47B

Special items of operating profit

-13.65%-2.26B

-48.70%-1.28B

-8.23%-1.99B

-110.78%-857.54M

2.47%-1.84B

-542.26%-406.85M

-143.49%-1.88B

-540.76%-63.35M

-14.13%-773.81M

-28.30%14.37M

Operating profit

7.51%13.08B

-8.04%7.04B

8.00%12.16B

5.31%7.65B

15.37%11.26B

13.64%7.27B

20.58%9.76B

27.31%6.4B

17.85%8.09B

13.80%5.02B

Financing income

-28.94%483.97M

-27.11%271.28M

15.90%681.1M

59.52%372.15M

-18.51%587.69M

--233.3M

--721.18M

----

Financing cost

11.19%-2.03B

14.58%-1.01B

4.38%-2.28B

17.60%-1.18B

2.74%-2.39B

---1.43B

---2.45B

----

Share of profits of associates

-28.82%261.96M

-43.03%113.24M

-11.77%368.01M

-6.25%198.77M

25.51%417.11M

14.04%212.01M

5.98%332.34M

30.26%185.91M

51.60%313.6M

89.37%142.73M

Earning before tax

7.92%11.8B

-8.94%6.42B

10.62%10.93B

12.14%7.05B

18.17%9.88B

-4.53%6.28B

-0.56%8.36B

27.39%6.58B

18.84%8.41B

15.07%5.17B

Tax

15.19%-2.14B

9.51%-1.36B

-20.02%-2.53B

-20.05%-1.51B

-23.61%-2.11B

11.23%-1.25B

3.29%-1.7B

-31.85%-1.41B

-0.52%-1.76B

-27.28%-1.07B

After-tax profit from continuing operations

14.87%9.65B

-8.79%5.05B

8.08%8.4B

10.17%5.54B

16.78%7.78B

-2.69%5.03B

0.16%6.66B

26.23%5.17B

24.87%6.65B

12.25%4.09B

Earning after tax

14.87%9.65B

-8.79%5.05B

8.08%8.4B

10.17%5.54B

16.78%7.78B

-2.69%5.03B

0.16%6.66B

26.23%5.17B

24.87%6.65B

12.25%4.09B

Minority profit

10.99%5.61B

1.38%2.98B

28.86%5.05B

25.06%2.94B

24.17%3.92B

9.53%2.35B

9.70%3.16B

29.40%2.14B

42.04%2.88B

54.71%1.66B

Profit attributable to shareholders

20.73%4.05B

-20.25%2.08B

-13.06%3.35B

-2.87%2.6B

10.11%3.85B

-11.35%2.68B

-7.13%3.5B

24.07%3.03B

14.31%3.77B

-5.40%2.44B

Basic earnings per share

20.75%0.64

-19.51%0.33

-13.11%0.53

-4.65%0.41

8.93%0.61

-10.42%0.43

-6.67%0.56

23.08%0.48

15.38%0.6

-4.88%0.39

Diluted earnings per share

20.75%0.64

-19.51%0.33

-13.11%0.53

-4.65%0.41

8.93%0.61

-10.42%0.43

-6.67%0.56

23.08%0.48

15.38%0.6

-4.88%0.39

Currency Unit

CNY

HKD

Accounting Standards

HKAS

Audit Opinions

Unqualified Opinion

Auditor

KPMG

Ernst & Young

	(FY)Dec 31, 2025	(Q6)Jun 30, 2025	(FY)Dec 31, 2024	(Q6)Jun 30, 2024	(FY)Dec 31, 2023	(Q6)Jun 30, 2023	(FY)Dec 31, 2022	(Q6)Jun 30, 2022	(FY)Dec 31, 2021	(Q6)Jun 30, 2021
Turnover	4.62%269.57B	2.54%131.87B	5.30%257.67B	4.71%128.6B	12.16%244.7B	-2.31%122.82B	-7.86%218.18B	9.81%125.72B	18.15%236.81B	28.08%114.49B
Operating income	4.62%269.57B	2.54%131.87B	5.30%257.67B	4.71%128.6B	12.16%244.7B	-2.31%122.82B	-7.86%218.18B	9.81%125.72B	18.15%236.81B	28.08%114.49B
Cost of sales	-3.72%-225.07B	-2.50%-110.36B	-5.15%-216.98B	-4.47%-107.66B	-11.81%-206.37B	2.67%-103.06B	8.37%-184.56B	-9.13%-105.88B	-19.80%-201.43B	-30.20%-97.02B
Operating expenses	-3.72%-225.07B	-2.50%-110.36B	-5.15%-216.98B	-4.47%-107.66B	-11.81%-206.37B	2.67%-103.06B	8.37%-184.56B	-9.13%-105.88B	-19.80%-201.43B	-30.20%-97.02B
Gross profit	9.39%44.51B	2.75%21.51B	6.13%40.69B	5.94%20.93B	14.04%38.34B	-0.36%19.76B	-4.98%33.62B	13.55%19.83B	9.56%35.38B	17.48%17.47B
Selling expenses	-11.50%-22.09B	-6.74%-10.01B	-4.76%-19.81B	-1.49%-9.38B	-15.34%-18.91B	-1.80%-9.24B	6.48%-16.4B	-9.59%-9.08B	-9.37%-17.53B	-22.35%-8.28B
Administrative expenses	-5.30%-7.08B	-4.67%-3.19B	-6.31%-6.73B	-7.00%-3.04B	-13.44%-6.33B	2.98%-2.85B	10.55%-5.58B	-8.58%-2.93B	-12.07%-6.24B	-25.74%-2.7B
Operating interest expense	----	----	----	----	----	----	----	7.39%-1.36B	12.96%-2.74B	5.32%-1.47B
Special items of operating profit	-13.65%-2.26B	-48.70%-1.28B	-8.23%-1.99B	-110.78%-857.54M	2.47%-1.84B	-542.26%-406.85M	-143.49%-1.88B	-540.76%-63.35M	-14.13%-773.81M	-28.30%14.37M
Operating profit	7.51%13.08B	-8.04%7.04B	8.00%12.16B	5.31%7.65B	15.37%11.26B	13.64%7.27B	20.58%9.76B	27.31%6.4B	17.85%8.09B	13.80%5.02B
Financing income	-28.94%483.97M	-27.11%271.28M	15.90%681.1M	59.52%372.15M	-18.51%587.69M	--233.3M	--721.18M	----	----	----
Financing cost	11.19%-2.03B	14.58%-1.01B	4.38%-2.28B	17.60%-1.18B	2.74%-2.39B	---1.43B	---2.45B	----	----	----
Share of profits of associates	-28.82%261.96M	-43.03%113.24M	-11.77%368.01M	-6.25%198.77M	25.51%417.11M	14.04%212.01M	5.98%332.34M	30.26%185.91M	51.60%313.6M	89.37%142.73M
Earning before tax	7.92%11.8B	-8.94%6.42B	10.62%10.93B	12.14%7.05B	18.17%9.88B	-4.53%6.28B	-0.56%8.36B	27.39%6.58B	18.84%8.41B	15.07%5.17B
Tax	15.19%-2.14B	9.51%-1.36B	-20.02%-2.53B	-20.05%-1.51B	-23.61%-2.11B	11.23%-1.25B	3.29%-1.7B	-31.85%-1.41B	-0.52%-1.76B	-27.28%-1.07B
After-tax profit from continuing operations	14.87%9.65B	-8.79%5.05B	8.08%8.4B	10.17%5.54B	16.78%7.78B	-2.69%5.03B	0.16%6.66B	26.23%5.17B	24.87%6.65B	12.25%4.09B
Earning after tax	14.87%9.65B	-8.79%5.05B	8.08%8.4B	10.17%5.54B	16.78%7.78B	-2.69%5.03B	0.16%6.66B	26.23%5.17B	24.87%6.65B	12.25%4.09B
Minority profit	10.99%5.61B	1.38%2.98B	28.86%5.05B	25.06%2.94B	24.17%3.92B	9.53%2.35B	9.70%3.16B	29.40%2.14B	42.04%2.88B	54.71%1.66B
Profit attributable to shareholders	20.73%4.05B	-20.25%2.08B	-13.06%3.35B	-2.87%2.6B	10.11%3.85B	-11.35%2.68B	-7.13%3.5B	24.07%3.03B	14.31%3.77B	-5.40%2.44B
Basic earnings per share	20.75%0.64	-19.51%0.33	-13.11%0.53	-4.65%0.41	8.93%0.61	-10.42%0.43	-6.67%0.56	23.08%0.48	15.38%0.6	-4.88%0.39
Diluted earnings per share	20.75%0.64	-19.51%0.33	-13.11%0.53	-4.65%0.41	8.93%0.61	-10.42%0.43	-6.67%0.56	23.08%0.48	15.38%0.6	-4.88%0.39
Currency Unit	CNY	CNY	CNY	CNY	CNY	CNY	CNY	HKD	HKD	HKD
Accounting Standards	HKAS	HKAS	HKAS	HKAS	HKAS	HKAS	HKAS	HKAS	HKAS	HKAS
Audit Opinions	--	--	Unqualified Opinion	--	Unqualified Opinion	--	Unqualified Opinion	--	Unqualified Opinion	--
Auditor	--	--	KPMG	--	KPMG	--	Ernst & Young	--	Ernst & Young	--

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

China and the United States have successively adjusted multiple tariff and non-tariff measures, beginning to implement the consensus outcome Show More

牛牛課堂

Oct 13, 2025 18:05

[Opportunity Express] The US-China rivalry escalates! The rare earth industry becomes a "game-changer." How should investors respond?

Food流油

Apr 14, 2025 15:43

"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"